aTyr Pharma (NASDAQ:LIFE) Shares Pass Above 200-Day Moving Average of $1.55

aTyr Pharma, Inc. (NASDAQ:LIFE) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.55 and traded as high as $1.61. aTyr Pharma shares last traded at $1.60, with a volume of 487,350 shares trading hands.

Analyst Upgrades and Downgrades

LIFE has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of aTyr Pharma in a research note on Friday. Royal Bank of Canada cut their target price on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.67.

aTyr Pharma Stock Up 0.6 %

The company’s 50-day moving average price is $1.77 and its 200 day moving average price is $1.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.27 and a current ratio of 6.27. The stock has a market cap of $109.38 million, a PE ratio of -1.79 and a beta of 1.27.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million. As a group, analysts forecast that aTyr Pharma, Inc. will post -0.97 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

Several hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its position in shares of aTyr Pharma by 5.1% during the 3rd quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock valued at $13,520,000 after buying an additional 413,162 shares in the last quarter. Pale Fire Capital SE lifted its holdings in aTyr Pharma by 425.8% during the fourth quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock valued at $414,000 after purchasing an additional 237,849 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of aTyr Pharma by 105.3% in the first quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 114,983 shares during the period. Kingswood Wealth Advisors LLC purchased a new stake in shares of aTyr Pharma in the first quarter worth $117,000. Finally, Granite Bay Wealth Management LLC bought a new stake in shares of aTyr Pharma during the 4th quarter valued at $25,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.